Mike Romanos Appointed as CEO of Crescendo Biologics

January 5, 2011

CAMBRIDGE, England, January 5, 2011 /PRNewswire/ — Crescendo Biologics
Limited (Crescendo) today announces the appointment of Mike Romanos as Chief
Executive Officer. Dr Romanos has been Chief Scientific Officer of the
company since May 2009 and has led the formation of the company and the
development of its proprietary antibody fragment technologies.

During this time, the company has made significant progress in the
establishment of its team and its technology platforms. This has included the
establishment of a colony of engineered mice completely devoid of endogenous
antibody polypeptides, announced in September. The proprietary ‘triple
knockout’ mice are believed to be unique and have the immunoglobulin heavy
chain (IgH), kappa light chain and lambda light chain loci all functionally
silenced by large-scale genomic deletion.

Dr Romanos has more than 23 years’ biotech and pharma industry experience
and within the last 10 years has held senior global positions leading major
parts of GlaxoSmithKline Discovery.

Clive Dix, Chairman of Crescendo said: “Today’s announcement reflects the
growing maturity of Crescendo and the progress the company has made under
Mike’s leadership. We have seen significant advances in the technology
platform and I am sure that with Mike now taking on the CEO position
Crescendo will deliver real value from its world class, proprietary
technology platforms and grow to become a leader in next-generation antibody

About Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment
technologies to the development of new targeted therapeutics. The Crescendo
transgenic mouse platform under development has the potential to rapidly and
predictably generate high-affinity human heavy chain antibodies that readily
yield VH fragments that have no requirement for humanisation. This is
combined with a powerful in vitro ribosome display technology which offers
significant advantages over existing approaches in antibody optimisation. VH
fragments provide great flexibility as a starting point for the development
of new targeted therapeutics combining the specificity and binding affinity
of antibodies with certain desirable characteristics of small molecules.

Crescendo’s technologies were invented by scientists at the Babraham
Institute, Cambridge (UK). The Company has raised GBP4.5 million in seed
funding from leading life sciences investors, Sofinnova Partners with Aitua,
Avlar BioVentures and the Rainbow Seed Fund also participating.


    Mike Romanos/Amanda Bettison
    Crescendo Biologics
    Tel: +44(0)1223-497140
    Email: mromanos/abettison@crescendobiologics.com

    Chris Gardner
    Citigate Dewe Rogerson
    Tel: +44(0)207-638-9571
    Email: chris.gardner@citigatedr.co.uk

SOURCE Crescendo Biologics

Source: newswire

comments powered by Disqus